For proper model selection in breast cancer research, the mutational landscape in breast cancer relevant genes should be considered for both inherited germline and somatic mutations in recurrently mutated genes (e.g. BRCA2, TP53), which might harbour tumour drivers [2, 3]. This evidence concerns the gene TP53 and neoplasm.